Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 547 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med 2020;382:6 de febrero. [Ref.ID 103518]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
4.Tiene citas relacionadas Cita con resumen
Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection?. Lancet 2017;390:107-9. [Ref.ID 101668]
6. Cita con resumen
Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016:23 de agosto. [Ref.ID 100599]
7. Cita con resumen
Mayor S. “Impressive results” in stem cell treatment for multiple sclerosis. BMJ 2016;353:i3269. [Ref.ID 100429]
8.Enlace a cita original Cita con resumen
Castañeda-Sanabria J, Hjage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 2016;72:737-46. [Ref.ID 100370]
9. Cita con resumen
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel J-F, Jouet J-P, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. Autologous hepatopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 2015;314:2524-34. [Ref.ID 99796]
11. Cita con resumen
Anónimo. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. U.S. Food and Drug Administration 2015:22 de octubre. [Ref.ID 99573]
12. Cita con resumen
Gulmez SE, Larrey D, Pageux G-P, Bernuau J, Bissoli F, Horsmans Y, Thorburn D, McCormick PA, Stricker B, Toussi M, Lignot-Maleyran S, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Moore N. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol 2015;80:599-606. [Ref.ID 99554]
13. Cita con resumen
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetnenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NH, Walewski J, for the AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853-62. [Ref.ID 99089]
14. Cita con resumen
Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers MED, Stevens-Ayers T, Jerome KR, Leisenring W. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 2015;162:1-10. [Ref.ID 98728]
15. Cita con resumen
Knoll G, Kokolo M, Mallick R, Beck A, Buenaventura C, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekbergh H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014;349:g6679. [Ref.ID 98345]
17.Tiene citas relacionadas
Thomas DL. A case for ribavirin to treat chronic hepatitis E. N Engl J Med 2014;370:1162-3. [Ref.ID 97312]
18.Tiene citas relacionadas Cita con resumen
Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, D'Alteroche L, Buchler M, Couzi L, Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM, Abravanel F, Pol S, Rostaing L, Mallet V. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20. [Ref.ID 97310]
19. Cita con resumen
Anónimo. Évérolimus après transplantation hépatique. Prescrire 2013;33:730. [Ref.ID 96230]
20. Cita con resumen
Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B. Choice of denominator in case population studies: event rates for registration for liver transplantation after exposure to NSIADs in the SALT study in France. Pharmacoepidemiol Drug Saf 2013;22:160-7. [Ref.ID 94867]
Seleccionar todas
 
 1 a 20 de 547 siguiente >>